To Check Dermatological Safety of Test Products by 24 Hours Patch Testing
Launched by NOVAMED LABORATORIES PVT. LTD. · Jul 2, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the skin safety of certain test products by applying them to the skin for 24 hours using a small patch. The goal is to see if these products cause any irritation or other skin reactions in healthy adults. The study is not yet recruiting participants.
To take part, you need to be between 18 and 65 years old, in good general health, and have normal to medium-dark skin tones (based on a common skin color scale). Both men and women can join, but women who could become pregnant must have a negative pregnancy test and not be breastfeeding. Participants should have no history of skin problems or current medications that might affect the results. During the study, you will have small patches applied to your back for 24 hours and will need to keep them in place while avoiding vigorous exercise. The researchers will check your skin before and after to see if there are any reactions. It’s important that participants follow all instructions and attend all study visits. If you have any active skin conditions, allergies to bandages, or are using certain medications, you may not be eligible. This study helps ensure that the products tested are safe for skin use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age: 18-65 years (both inclusive) at the time of consent.
- • 2. Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
- • 3. Subject with normal Fitzpatrick skin type III to V (Human skin colour determination scale).
- • 4. Females of childbearing potential must have a self-reported negative pregnancy test.
- • 5. Subject who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results.
- • 6. Subject is in good general health as determined by the Investigator on the basis of medical history.
- • 7. Subjects is willing to maintain the test patches in designated positions for 24 Hours.
- • 8. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
- • 9. Subject must be able to understand and provide written informed consent to participate in the study.
- • 10. Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given.
- 11. For Sensitive Specific Skin Study Only:
- • Subject scoring greater than 30 for Section 2 - Sensitive v/s Resistant skin in modified Dr Baumann's\* skin type questionnaire.
- • Subject with sensitive skin as confirmed by Lactic Acid Stinging Test.
- Exclusion Criteria:
- • 1. Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.
- • 2. Medication which may affect skin response and/or past medical history.
- • 3. Subject having history of diabetes
- • 4. Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
- • 5. Subject suffering from any active clinically significant skin diseases which may contraindicate.
- • 6. Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer.
- • 7. Participation in any patch test for irritation or sensitization within the last four weeks.
- • 8. Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).
- 9. Use of any:
- • i. Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application.
- • ii. Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application.
- • iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and/or eye drops are permitted)
- • 10. Topical drugs used at application site.
- • 11. Subject with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous.
- • 12. Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.
- • 13. Subject with known allergy or sensitization to medical adhesives, bandages.
- • 14. Participation in other patch study simultaneously.
About Novamed Laboratories Pvt. Ltd.
Novamed Laboratories Pvt. Ltd. is a reputable pharmaceutical company dedicated to advancing healthcare through innovative research and development. Specializing in clinical trials, Novamed focuses on delivering high-quality, safe, and effective medical solutions. With a commitment to excellence and compliance with global regulatory standards, the company plays a vital role in the development and evaluation of new therapies aimed at improving patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Nayan Patel
Principal Investigator
NovoBliss Research Private Limited
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported